Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
Yasser Rehman1, Jonathan E Rosenberg21Division of Hospital Medicine, UMass Memorial Healthcare, Worcester, MA, USA; 2Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Prostate cancer is the second leading cause of cancer death in m...
Main Authors: | Rosenberg JE, Rehman Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-01-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/abiraterone-acetate-oral-androgen-biosynthesis-inhibitor-for-treatment-a9062 |
Similar Items
-
Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01) -
Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma
by: R Nandha
Published: (2012-01-01) -
Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01) -
Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01) -
Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
by: Yutaka Yamamoto, et al.
Published: (2018-01-01)